MCID: PRC016
MIFTS: 65

Pre-Eclampsia

Categories: Rare diseases, Reproductive diseases, Cardiovascular diseases

Aliases & Classifications for Pre-Eclampsia

MalaCards integrated aliases for Pre-Eclampsia:

Name: Pre-Eclampsia 12 24 41 14 69
Preeclampsia 12 72 24 55 28 51
Pregnancy Associated Hypertension 12 69
Proteinuric Hypertension of Pregnancy 12
Gestational Proteinuric Hypertension 24
Transient Hypertension of Pregnancy 69
Hypertension Induced by Pregnancy 12
Pregnancy-Induced Hypertension 24
Gestational Hypertension 12
Pre-Eclamptic Toxaemia 12
Preeclampsia/eclampsia 12
Toxaemia of Pregnancy 12
Toxemia of Pregnancy 24
Pregnancy Toxemias 51
Pregnancy Toxemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10591
MeSH 41 D011225
Orphanet 55 ORPHA275555
UMLS via Orphanet 70 C0032914
ICD10 via Orphanet 33 O14.0 O14.1 O14.2 more

Summaries for Pre-Eclampsia

Genetics Home Reference : 24 Preeclampsia is a complication of pregnancy in which affected women develop high blood pressure (hypertension); they can also have abnormally high levels of protein in their urine (proteinuria). This condition usually occurs in the last few months of pregnancy and often requires early delivery of the infant.

MalaCards based summary : Pre-Eclampsia, also known as preeclampsia, is related to mild pre-eclampsia and severe pre-eclampsia, and has symptoms including morning sickness, hyperemesis gravidarum and edema. An important gene associated with Pre-Eclampsia is STOX1 (Storkhead Box 1), and among its related pathways/superpathways are VEGF Pathway (Qiagen) and VEGF Signaling Pathway. The drugs Methyldopa and Calcium Carbonate have been mentioned in the context of this disorder. Affiliated tissues include endothelial, placenta and testes, and related phenotypes are cardiovascular system and growth/size/body region

Disease Ontology : 12 A hypertension occurring during pregnancy characterized by large amounts of protein in the urine (proteinuria) and edema, usually by the last trimester of pregnancy.

Wikipedia : 72 Pre-eclampsia (PE) is a disorder of pregnancy characterized by the onset of high blood pressure and... more...

Related Diseases for Pre-Eclampsia

Diseases in the Eclampsia family:

Pre-Eclampsia Severe Pre-Eclampsia

Diseases related to Pre-Eclampsia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 209)
# Related Disease Score Top Affiliating Genes
1 mild pre-eclampsia 35.3 FLT1 LEP PGF
2 severe pre-eclampsia 35.2 F5 HLA-G LEP LGALS13 PGF SERPINC1
3 preeclampsia/eclampsia 1 33.7 EPHX1 NOS3 PEE1
4 eclampsia 33.5 CORIN EDN1 ENG EPHX1 F5 FLT1
5 hellp syndrome 33.4 EDN1 ENG F5 FLT1 LGALS13 MTHFR
6 placental insufficiency 31.5 FLT1 LEP PGF VEGFA
7 placental abruption 31.3 ENG F5 FLT1 MTHFR PGF SERPINC1
8 pulmonary edema 31.0 EDN1 NOS3 SERPINC1
9 antiphospholipid syndrome 31.0 F5 MTHFR SERPINC1
10 vascular disease 31.0 EDN1 F5 MTHFR NOS3 SERPINC1 VEGFA
11 microvascular complications of diabetes 5 30.9 FLT1 NOS3 PGF VEGFA
12 central retinal vein occlusion 30.7 F5 MTHFR SERPINC1 VEGFA
13 retinal vein occlusion 30.7 F5 MTHFR SERPINC1 VEGFA
14 antithrombin iii deficiency 30.7 F5 MTHFR SERPINC1
15 portal vein thrombosis 30.7 F5 MTHFR SERPINC1
16 thrombosis 30.6 F5 MTHFR SERPINC1
17 preeclampsia/eclampsia 4 12.0
18 preeclampsia/eclampsia 5 12.0
19 gestational diabetes 11.5
20 glomeruloid hemangioma 10.8 ENG FLT1 VEGFA
21 epithelioid hemangioendothelioma 10.8 FLT1 PGF VEGFA
22 cancer-associated retinopathy 10.8 FLT1 PGF VEGFA
23 hemifacial spasm 10.8 MTHFR NOS3 VEGFA
24 twin-to-twin transfusion syndrome 10.8 ENG FLT1 PGF
25 vascular cancer 10.8 ENG FLT1 VEGFA
26 pregnancy loss, recurrent 1 10.8 F5 HLA-G MTHFR
27 chronic mountain sickness 10.8 EDN1 NOS3 VEGFA
28 acute mountain sickness 10.8 EDN1 FLT1 NOS3 VEGFA
29 limb ischemia 10.8 EDN1 NOS3 PGF VEGFA
30 persistent fetal circulation syndrome 10.8 EDN1 NOS3 PGF
31 arteritic anterior ischemic optic neuropathy 10.8 F5 MTHFR NOS3
32 inferior vena cava interruption 10.8 F5 MTHFR
33 prinzmetal's variant angina 10.8 EDN1 NOS3
34 hepatopulmonary syndrome 10.8 EDN1 NOS3 VEGFA
35 retinal vascular disease 10.8 FLT1 MTHFR VEGFA
36 spinal cord infarction 10.7 F5 MTHFR SERPINC1
37 sudden sensorineural hearing loss 10.7 F5 MTHFR SERPINC1
38 angiokeratoma circumscriptum 10.7 FLT1 VEGFA
39 retinal artery occlusion 10.7 F5 MTHFR SERPINC1
40 amaurosis fugax 10.7 F5 MTHFR
41 placenta disease 10.7 F5 MTHFR PGF SERPINC1
42 intracranial thrombosis 10.7 F5 MTHFR SERPINC1
43 thrombophlebitis 10.7 F5 MTHFR SERPINC1
44 hereditary hemorrhagic telangiectasia 10.7 ENG NOS3 VEGFA
45 varicose veins 10.7 F5 MTHFR SERPINC1 VEGFA
46 protein s deficiency 10.7 F5 MTHFR SERPINC1
47 portal hypertension 10.7 EDN1 NOS3 VEGFA
48 retinal vascular occlusion 10.7 F5 MTHFR PGF SERPINC1 VEGFA
49 hepatic vascular disease 10.7 EDN1 MTHFR NOS3 SERPINC1
50 vein disease 10.7 F5 MTHFR SERPINC1

Graphical network of the top 20 diseases related to Pre-Eclampsia:



Diseases related to Pre-Eclampsia

Symptoms & Phenotypes for Pre-Eclampsia

UMLS symptoms related to Pre-Eclampsia:


morning sickness, hyperemesis gravidarum, edema

MGI Mouse Phenotypes related to Pre-Eclampsia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.02 CORIN EDN1 ENG F5 FLT1 LEP
2 growth/size/body region MP:0005378 9.93 CORIN EDN1 ENG F5 FLT1 LEP
3 embryo MP:0005380 9.86 EDN1 ENG F5 FLT1 LEP PGF
4 homeostasis/metabolism MP:0005376 9.83 CORIN EDN1 ENG EPHX1 F5 FLT1
5 muscle MP:0005369 9.17 CORIN EDN1 ENG FLT1 LEP NOS3

Drugs & Therapeutics for Pre-Eclampsia

Drugs for Pre-Eclampsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 405)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyldopa Approved Phase 4,Phase 2,Phase 1 555-30-6 38853
2
Calcium Carbonate Approved, Investigational Phase 4,Phase 3 471-34-1
3
Remifentanil Approved Phase 4,Phase 2,Phase 1 132875-61-7 60815
4
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 4091 14219
5
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2 38396-39-3, 2180-92-9 2474
6
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
7
Dalteparin Approved Phase 4,Phase 2,Phase 3 9005-49-6
8
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3 9005-49-6 46507594 772
9
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3 7440-66-6 32051 23994
10
Ephedrine Approved Phase 4,Phase 3,Phase 2 299-42-3 9294
11
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
12
Phenylephrine Approved Phase 4 59-42-7 6041
13
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2 90-82-4 7028
14
Labetalol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 36894-69-6 3869
15
Misoprostol Approved Phase 4,Phase 3,Phase 1,Phase 2 59122-46-2 5282381
16
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
17
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
18
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 7487-88-9 24083
19
Furosemide Approved, Vet_approved Phase 4,Phase 2 54-31-9 3440
20
Captopril Approved Phase 4 62571-86-2 44093
21
Clonidine Approved Phase 4,Phase 1,Phase 2 4205-90-7 2803
22
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
23
Insulin Aspart Approved Phase 4,Phase 3 116094-23-6 16132418
24
Insulin Lispro Approved Phase 4 133107-64-9
25
Glyburide Approved Phase 4 10238-21-8 3488
26
Nifedipine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 21829-25-4 4485
27
Acetaminophen Approved Phase 4,Phase 2,Phase 3 103-90-2 1983
28
Ibuprofen Approved Phase 4,Phase 2,Phase 3 15687-27-1 3672
29
Thrombin Approved, Investigational Phase 4
30
Azithromycin Approved Phase 4,Phase 3 83905-01-5 53477736 447043 55185
31
Desogestrel Approved Phase 4 54024-22-5 40973
32
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
33
Amlodipine Approved Phase 4 88150-42-9 2162
34
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 77-92-9 311
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
36
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 58-05-9 143 6006
37
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2 67-97-0 10883523 5280795 6221
38
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1,Phase 2 50-14-6 5280793
39
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 1406-16-2
40 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Not Applicable
41 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
42 Bone Density Conservation Agents Phase 4,Phase 3,Phase 1,Phase 2
43 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
44 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
45 Adrenergic Agonists Phase 4,Phase 2,Phase 3,Phase 1
46 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 2,Phase 3,Phase 1
47 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3,Phase 1
48 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
49 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
50 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 593)

# Name Status NCT ID Phase Drugs
1 Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape) Unknown status NCT01361425 Phase 4 methildopa;placebo
2 Low Dose Calcium to Prevent Preeclampsia Unknown status NCT02338687 Phase 4
3 Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia Unknown status NCT00117546 Phase 4 alpha methyldopa
4 Remifentanil for General Anesthesia in Preeclamptics Unknown status NCT00567957 Phase 4 Remifentanil;Saline
5 Viagra for the Treatment of IUGR Unknown status NCT00347867 Phase 4 Viagra administration in IUGR/PET pregnancies
6 Metformin and Gestational Diabetes in High-risk Patients: a RCTs Unknown status NCT00883259 Phase 4 Metformin
7 Effectiveness of Metformin in Recurrent Miscarriage in a Woman With Hyperinsulinaemia Unknown status NCT01718340 Phase 4 Metformin
8 Adding MgSO4 to Epidural Levobupivacaine in CS for Patients With Preeclampsia Completed NCT02699827 Phase 4 Levobupivacaine hydrochloride;Magnesium sulphate;Saline 0.9%
9 Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers Completed NCT01729468 Phase 4 Aspirin;Placebo
10 Treatment Approaches to Preeclampsia Completed NCT01030627 Phase 4
11 Diuretics for Postpartum High Blood Pressure in Preeclampsia Completed NCT02163655 Phase 4 FUROSEMIDE;Placebo
12 A Study of Cerebral-circulatory Response to Intravenous Antihypertensive Treatment in Women With Serious Preeclampsia Completed NCT00403572 Phase 4
13 Hemodynamic Measurements in Women With Serious Preeclampsia Completed NCT00199810 Phase 4
14 Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia Completed NCT01352234 Phase 4 Acetylsalicylic Acid;Acetylsalicylic Acid
15 Effectiveness Study of Short Course of Magnesium Sulfate for Severe Preeclamsia Completed NCT01408979 Phase 4 Magnesium sulfate 12 hours;Magnesium sulfate 24 hours
16 A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen Completed NCT02091401 Phase 4 Magnesium Sulfate
17 Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure Completed NCT01761916 Phase 4 CLONIDINE;CAPTOPRIL
18 Effects of Magnesium Sulphate on Sugammadex Reversal of Rocuronium Induced Blockade in Gynaecology Patients Completed NCT01972659 Phase 4 placebo;Magnesium Sulphate;sugammadex
19 Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies Completed NCT01608347 Phase 4 LMWH+Folic acid;Folic Acid
20 Metformin Versus Insulin in Gestational Diabetes Completed NCT01240785 Phase 4 metformin;insulin
21 Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) Patients Completed NCT02466204 Phase 4 corifollitropin alfa;Follitropin Beta
22 Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo Completed NCT00744965 Phase 4 Glyburide;Placebo
23 Impact of Antichlamydial Treatment on the Rate of Preeclampsia Recruiting NCT03233880 Phase 4 Azithromycin 1gm
24 Efficacy and Safety of 1 g Vs 2 g Per Hour Intravenous Maintenance Dose of MgSO4 in Women With Severe Pre-eclampsia Recruiting NCT03164304 Phase 4 Magnesium Sulfate
25 Phenylephrine Versus Ephedrine in Pre-eclampsia Recruiting NCT02025426 Phase 4 Phenylephrine;Ephedrine
26 A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy Recruiting NCT02920593 Phase 4 Vitamin D3
27 Early Vascular Adjustments During Hypertensive Pregnancy Recruiting NCT02531490 Phase 4 Labetalol;Nifedipine;Methyldopa
28 Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy Recruiting NCT01912677 Phase 4 Nifedipine;Labetalol;Methyldopa
29 Chronotherapy With Low-dose Aspirin for Primary Prevention Recruiting NCT00725127 Phase 4 aspirin;aspirin
30 Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology Recruiting NCT03177122 Phase 4 Myo-inositol
31 A Comparison of Oral Misoprostol and Vaginal Misoprostol for Cervical Ripening and Induction of Labor Recruiting NCT02777190 Phase 4 Misoprostol
32 Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features Active, not recruiting NCT02911701 Phase 4 Acetaminophen;Ibuprofen
33 The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy Active, not recruiting NCT02891174 Phase 4 Ibuprofen;Acetaminophen
34 Contraception in Women With Sickle Cell Disease Active, not recruiting NCT02594462 Phase 4 etonogestrel-releasing implant contraceptive
35 Pharmacokinetics of Amlodipine Besylate at Delivery and During Lactation Active, not recruiting NCT02353806 Phase 4 Amlodipine besylate
36 Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial Not yet recruiting NCT03318211 Phase 4 Magnesium Sulfate
37 Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients Not yet recruiting NCT03237000 Phase 4 MgSO4
38 Failure Rate of GLyburide And Metformin Among Gestational Diabetics Not yet recruiting NCT03078725 Phase 4 Glyburide;Metformin
39 LMWH to Prevent Preeclampsia and Fetal Growth Restriction Terminated NCT00260520 Phase 4 Dalteparin
40 Different Schemes of Magnesium Sulfate for Preeclampsia Terminated NCT02396030 Phase 4 Magnesium sulfate 50% - 1g/h;Magnesium sulfate 50% - 2g/h
41 Comparison of Awakening Versus Bedtime Dosing of Aspirin in Pre-Hypertension or Mild Essential Hypertension Terminated NCT00449618 Phase 4 Aspirin 100 mg;Placebo
42 Atenativ Effect on Uterine Blood Flow and Preeclampsia Withdrawn NCT02278575 Phase 4 Atenativ
43 Low Dose Aspirin for the Prevention of Preeclampsia Unknown status NCT01890005 Phase 3 Aspirin;Placebo
44 PP13 and Doppler Study to Predict Preeclampsia Unknown status NCT00928213 Phase 2, Phase 3 Progesterone;Low molecular weight Heparin;No Drug
45 Investigating the Novel Observation of Right-Left Difference in Uterine Artery Vascular Resistance in Pre-Eclampsia Unknown status NCT00848679 Phase 3 Epidural lidocaine;Epidural lidocaine 2%
46 Carbetocin vs. Oxytocin for Prevention of Postpartum Bleeding in Patients With Severe Preeclampsia Unknown status NCT01382732 Phase 3 Carbetocin;Oxytocin
47 Treatment of Severe Hypertension During Pre-Eclampsia: A Preliminary Equivalence Study Between Urapidil and Nicardipine Unknown status NCT00409253 Phase 3 URAPIDIL (EUPRESSYL*);NICARDIPINE
48 Randomized Clinical Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients. Unknown status NCT02050529 Phase 2, Phase 3 Labetalol;Hydralazine
49 A Randomized Clinical Trial of Oral Magnesium Supplementation in Pregnancy Unknown status NCT02032186 Phase 3 Magnesium citrate
50 Effect of Micronutrients and Exercise During Pregnancy on Factors Related With Non-Transmissible Chronic Diseases Unknown status NCT00872365 Phase 2, Phase 3

Search NIH Clinical Center for Pre-Eclampsia

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: pre-eclampsia

Genetic Tests for Pre-Eclampsia

Genetic tests related to Pre-Eclampsia:

# Genetic test Affiliating Genes
1 Preeclampsia 28

Anatomical Context for Pre-Eclampsia

MalaCards organs/tissues related to Pre-Eclampsia:

38
Endothelial, Placenta, Testes, Lung, Liver, Kidney, Thyroid

Publications for Pre-Eclampsia

Articles related to Pre-Eclampsia:

(show top 50) (show all 1537)
# Title Authors Year
1
Elabela-APJ axis contributes to embryonic development and prevents pre-eclampsia in pregnancy. ( 29342224 )
2018
2
Re: Placental histopathology associated with pre-eclampsia: a systematic review and meta-analysis. ( 29417682 )
2018
3
Pre-Eclampsia and Eclampsia: An Update on the Pharmacological Treatment Applied in Portugal. ( 29367581 )
2018
4
Maternal cardiac output response to colloid preload and vasopressor therapy during spinal anaesthesia for caesarean section in patients with severe pre-eclampsia: a randomised, controlled trial. ( 29086911 )
2018
5
Decidual regulation of trophoblast is altered in pregnancies at risk of pre-eclampsia. ( 29437882 )
2018
6
Association between fetal fraction on cell-free DNA testing and first trimester markers for pre-eclampsia. ( 29318732 )
2018
7
Aspirin non-responsiveness in pregnant women at high-risk of pre-eclampsia. ( 29304392 )
2018
8
Induction of systemic inflammation by hyaluronan and hsp70 in women with pre-eclampsia. ( 29438905 )
2018
9
Combination of first trimester serum afamin levels and three-dimensional placental bed vascularization as a possible screening method to detect women at-risk for adverse pregnancy complications like pre-eclampsia and gestational diabetes mellitus in low-risk pregnancies. ( 29405972 )
2018
10
Pre-eclampsia affects procalcitonin production in placental tissue. ( 29427369 )
2018
11
Dexmedetomidine as a part of general anaesthesia for caesarean delivery in patients with pre-eclampsia: Efficacy and foetal outcome: a randomised double-blinded trial. ( 29432379 )
2018
12
A case of partial hydatidiform molar pregnancy with a placental diploid-triploid mosaicism associated with a euploid viable foetus complicated with severe pre-eclampsia. ( 29421928 )
2018
13
Pre-eclampsia and the risk of autism-spectrum disorder in offspring: meta-analysis. ( 29436313 )
2018
14
Study on the correlation between adipocyte fatty-acid binding protein, glucolipid metabolism, and pre-eclampsia. ( 29316087 )
2018
15
Prediction and prevention of pre-eclampsia in Asian subpopulation. ( 29442407 )
2018
16
Is it time to move towards non-invasive prenatal screening for Down syndrome and screening for pre-eclampsia? ( 29446241 )
2018
17
Twin gestation in a Swyer syndrome patient with superimposed pre-eclampsia. ( 29421927 )
2018
18
What are the metabolic precursors which increase the risk of pre-eclampsia and how could these be investigated further. ( 28855067 )
2017
19
Pre-eclampsia: Molecular events to biomarkers. ( 28924318 )
2017
20
Accuracy of competing risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. ( 28067011 )
2017
21
Circulating adipokines are associated with pre-eclampsia in women with type 1 diabetes. ( 28875223 )
2017
22
Shared biomarkers between female diastolic heart failure and pre-eclampsia: a systematic review and meta-analysis. ( 28451444 )
2017
23
Severe pre-eclampsia is associated with alterations in cytotrophoblasts of the smooth chorion. ( 28232601 )
2017
24
Maternal bradycardia occurring prior to onset of HELLP syndrome in a woman with pre-eclampsia. ( 28501825 )
2017
25
Serious Visual (Ocular) Complications in Pre-eclampsia and Eclampsia. ( 28867885 )
2017
26
Response to: Using Carbon Monoxide Releasing Molecules in Models of Pre-Eclampsia: When Should We Be Monitoring Vascular Effects? ( 28911026 )
2017
27
Oligohydramnios is an independent risk factor for perinatal morbidity among women with pre-eclampsia who delivered preterm. ( 29237307 )
2017
28
Re: Pre-eclampsia: an important risk factor for asymptomatic heart failure. C. Ghossein-Doha, J. van Neer, B. Wissink, N. Breetveld, L. J. de Windt, A. P. J. van Dijk, M. J. van der Vlugt, M. C. H. Janssen, W. M. Heidema, R. R. Scholten and M. E. A. Spaanderman. Ultrasound Obstet Gynecol 2017; 49: 143-149. ( 28058791 )
2017
29
Severe pre-eclampsia before 26A weeks of gestation: how should we counsel women? ( 28229528 )
2017
30
Pre-eclampsia is primarily a placental disorder: FOR: Pre-eclampsia is primarily a placental disorder. ( 28921791 )
2017
31
Evaluation of Placental mir-155-5p and Long Non-coding RNA sONE Expression in Patients with Severe Pre-eclampsia. ( 28868266 )
2017
32
Screening for pre-eclampsia in the first trimester: what do we still need to know before starting? ( 28850746 )
2017
33
Cardio-metabolic Risk Profile in Women with Previous History of Pre-Eclampsia. ( 29313572 )
2017
34
Hypertension: A new genetic clue to unravel the origins of pre-eclampsia. ( 28869250 )
2017
35
Elevated microRNA-520g in pre-eclampsia inhibits migration and invasion of trophoblasts. ( 28292471 )
2017
36
Isolated sixth Cranial Nerve Palsy in a Case Of Severe Pre-Eclampsia Presenting as Postpartum Diplopia. ( 28969214 )
2017
37
Validation of fullPIERS model for prediction of adverse outcomes among women with severe pre-eclampsia. ( 28475234 )
2017
38
Liver disease late in pregnancy without pre-eclampsia. ( 29364098 )
2017
39
Evaluation of the predictive value of placental vascularisation indices derived from 3-Dimensional power Doppler whole placental volume scanning for prediction of pre-eclampsia: A systematic review and meta-analysis. ( 28089506 )
2017
40
The effects of sildenafil citrate on uterine angiogenic status and serum inflammatory markers in an L-NAME rat model of pre-eclampsia. ( 27940055 )
2017
41
Validation of Fetal Medicine Foundation algorithm for prediction of pre-eclampsia in the first trimester in an unselected Brazilian population. ( 28889785 )
2017
42
Determinants of magnesium sulphate use in women hospitalized at <29 weeks with severe or non-severe pre-eclampsia. ( 29272274 )
2017
43
Prediction of severe pre-eclampsia by a combination of sFlt-1, CT-pro ET1 and blood pressure: exploratory study. ( 28643875 )
2017
44
Preterm pre-eclampsia: What every neonatologist should know. ( 28917582 )
2017
45
Evaluation of MicroRNA-210 and Protein tyrosine phosphatase, non-receptor type 2 in Pre-eclampsia. ( 27746364 )
2017
46
Comment on: Maternal pre-eclampsia as a risk factor for necrotizing enterocolitis. ( 28911253 )
2017
47
Re: Serious maternal complications in relation to severe pre-eclampsia: a retrospective cohort study of the impact of hospital volume; Severe maternal morbidity requires regionalisation of obstetric critical care; Guilt, blame and litigation: can an overenthusiastic 'safety culture' cause harm?: Maternal mortality: the heavy psychological burden on centre obstetricians. ( 28670731 )
2017
48
Introduction of management protocol for early-onset severe pre-eclampsia. ( 28150368 )
2017
49
Re: Endothelial dysfunction and vascular stiffness in women with previous pregnancy complicated by early or late pre-eclampsia. R. Orabona, E. Sciatti, E. Vizzardi, I. Bonadei and A. Valcamonico. Ultrasound Obstet Gynecol 2017; 49: 116-123. ( 28058790 )
2017
50
Study of Association of Thyroid Hormone in Pre-Eclampsia and Normal Pregnancy. ( 29322709 )
2017

Variations for Pre-Eclampsia

ClinVar genetic disease variations for Pre-Eclampsia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 NOS3 NM_000603.4(NOS3): c.894T> G (p.Asp298Glu) single nucleotide variant risk factor rs1799983 GRCh37 Chromosome 7, 150696111: 150696111
2 NSD1 NM_022455.4(NSD1): c.6050G> A (p.Arg2017Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587784177 GRCh38 Chromosome 5, 177283827: 177283827

Copy number variations for Pre-Eclampsia from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 44882 10 64500000 74900000 Loss STOX1 Preeclampsia

Expression for Pre-Eclampsia

Search GEO for disease gene expression data for Pre-Eclampsia.

Pathways for Pre-Eclampsia